logo-loader
viewOptiBiotix Health PLC

OptiBiotix Health receives line extension to European regulatory sign-off

"This line extension will help us convert the commercial opportunities we are working on into distribution agreements," said Dr Fred Narbel, managing director of OptiBiotix's prebiotics division

OptiBiotix Health PLC -

OptiBiotix Health PLC (LON:OPTI) has received European regulatory sign-off for the unflavoured version of SlimBiome Medical.

The CE Mark provides a product line extension for the firm's weight loss sachets after initial approval last November.  

It allows the company to offer the 'plain' version of the line with natural flavour boosters for "minimal" additional expenditure.

The combination also provides a cost saving element as OptiBiotix now doesn’t have to register new flavours for individual regulatory sign-off.

“This line extension will help us convert the commercial opportunities we are working on into distribution agreements," said Dr Fred Narbel, managing director of OptiBiotix's prebiotics division.

As well as developing weight loss products, the AIM-listed sciences company has created compounds to tackle high cholesterol, diabetes and for use in skin care.

Its focus is controlling the interactions of human microbiome, an ecosystem of bacteria which resides in the gut and on the skin.

Quick facts: OptiBiotix Health PLC

Price: 50.9 GBX

AIM:OPTI
Market: AIM
Market Cap: £43.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

3 days ago

2 min read